Ligand Avinza Once-Daily Dosing Will Be Core Promo Message For Elan Opioid

Ligand will focus on Avinza once-daily dosing as the opioid's primary marketing message following the March 20 approval of the extended-release morphine drug licensed from Elan

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet